Bioinformatics

Bioinformatics is at the cutting edge of modern life sciences, driving innovation across diagnostics, therapeutics, and personalised medicine. By harnessing biological data and applying computational tools, researchers are uncovering new insights into disease, developing in silico drug discovery platforms, and predicting patient outcomes with unprecedented precision.

Protecting these innovations requires a sophisticated intellectual property strategy that understands both biological complexity and software-driven processes. HGF has a long-standing reputation for IP excellence in life sciences and data-centric technologies, making us ideally placed to support bioinformatics innovators.

Our expertise includes:

  • AI and machine learning models trained on biological data
  • Genomic analysis and personalised medicine platforms
  • Computational biology tools and software pipelines
  • Data integration, visualisation, and analytics systems
  • Expert guidance on patentability of algorithms, databases and diagnostic methods under European patent law
  • Coordinating parallel patent strategies across EP, national and international filing routes

From spinouts leveraging university research to global pharmaceutical companies developing next-generation therapies, we work with a broad range of clients to protect core technologies and support commercial success.

We understand the particular challenges of patenting bioinformatics inventions, from hybrid software/biotech technologies to patentability requirements in software and AI innovations. Our attorneys provide commercially focused IP strategies that align with your R&D roadmap, regulatory environment, and funding goals.

Our integrated approach draws on a wealth of technical and legal knowledge across disciplines, combining life sciences, software, and medical regulation expertise. We offer a full suite of IP protection tools, including patents, trade secrets, copyright, and database rights.

At HGF, we don’t just file patents, we help shape your competitive advantage in a fast-evolving market. Partner with us for IP strategies that secure your position at the forefront of bioinformatics innovation.

Latest updates

Building to Survive: Designing Life Sciences Patent Portfolios to Withstand a Challenge

The strongest life sciences IP strategies are not designed simply just to obtain a series of patents. They are designed around the challenges those patents may have to withstand five, …

Read article

HGF Presents - Protecting Plant Innovation

In this video, we explore the statutory and regulatory barriers to the patentability of plant-related inventions in the US and Europe, before considering the landscapes further afield. Given the divergent …

Read article
Event - 12th November 2026

HGF Partners with PPTI for 'Designing Foods for Healthy Aging' Webinar

As healthy aging, metabolic health and weight management rise up the consumer agenda, food and nutrition businesses are increasingly looking beyond traditional product development and towards solutions that deliver measurable …

Event details
Event - 15th December 2026

Basel Seminar: Seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU

Venue – Der Teufelhof Basel, Switzerland We are pleased to invite you to our seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU. …

Event details

Where Does the Real IP Value Lie in AI-Enabled Life Sciences?

After attending the BioTechX conference in Basel last week, talking to people working across pharma, biotech, AI, software, laboratory automation and data management, my main takeaway was clear: the conversation …

Read article

When AI Designs the Ingredient: Who Controls the Data, the Model and the Discovery?

AI-enabled discovery has drawn significant attention in pharmaceutical R&D, but its impact is extending into other industries, across ingredients, food, flavour, fragrance and industrial biotechnology. As AI models advance, the …

Read article

Protecting the AI Drug Discovery Ecosystem: Building an IP Stack Around Targets, Molecules and Medicines

Despite the considerable costs and effort in target identification, candidate generation, selection and advancement to clinical trials, 90% of candidates that enter clinical trials during drug discovery fail (Sun D, …

Read article

Agritech Thymes: UK-EU SPS agreement – what does it mean for plant breeders?

Since Brexit, the UK agrifood sector has faced difficulties, largely due to the requirement for additional certifications and controls, such as phytosanitary certificates and border checks. This has had a …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our bioinformatics specialists.